Medtronic earns FDA approval for 'smart' heart defibrillator

The Food and Drug Administration approved Dublin-based Medtronic's Claria MRI Quad Cardiac Resynchronization Therapy Defibrillator for patients with heart failure.

The Claria MRI CRT-D contains built-in software that uses an algorithm to assess the effectiveness of pulses sent to a patient's heart and adjust the rate of the pulses accordingly, according to a news release.

"Until now, CRT devices have shown only whether a pacing pulse was sent, but we haven't been able to determine if that stimulation actually improves the heart's pumping ability," said Suneet Mittal, MD, director of the Electrophysiology Laboratory at the Arrhythmia Institute of Valley Health System in Ridgewood, N.J. "Physicians are now able to verify the effectiveness of left ventricular pacing, which is especially beneficial for improving outcomes in patients with atrial fibrillation."

Medtronic did not indicate when the device would hit the market.

More articles on supply chain:

FDA rejects Dynavax's hep B vaccine…again
How will President-elect Donald Trump's policies affect medtech and pharma?
Novartis' leukemia drug earns priority review status

Copyright © 2023 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.


Featured Whitepapers

Featured Webinars